Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACSTNYSE:ETXCVE:NVHNASDAQ:RENENYSE:UPC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACSTAcasti Pharma$3.11$3.22$1.98▼$3.60$29.23M1.5222,722 shs12,261 shsETXEaton Vance Municipal Income 2028 Term Trust$18.04$18.15$17.48▼$19.44N/AN/A22,052 shs25,176 shsNVHNovoheartC$0.53+1.9%C$0.53C$0.26▼C$0.72C$99.98MN/A33,593 shs23,066 shsRENECartesian Growth Co. II$11.75$11.79$11.28▼$11.95$254.05M-0.0199,374 shs1 shsUPCUniverse Pharmaceuticals$3.75+2.7%$4.51$2.51▼$2,592.00$161K1.51175,100 shs41,257 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACSTAcasti Pharma0.00%0.00%0.00%-7.72%+6.51%ETXEaton Vance Municipal Income 2028 Term Trust+0.08%0.00%-1.56%-0.99%-3.53%NVHNovoheart0.00%0.00%0.00%0.00%0.00%RENECartesian Growth Co. II0.00%0.00%0.00%-1.09%+4.21%UPCUniverse Pharmaceuticals+2.74%-0.53%-21.88%+31.12%-99.75%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACSTAcasti Pharma1.7123 of 5 stars3.50.00.00.00.00.81.3ETXEaton Vance Municipal Income 2028 Term TrustN/AN/AN/AN/AN/AN/AN/AN/ANVHNovoheartN/AN/AN/AN/AN/AN/AN/AN/ARENECartesian Growth Co. IIN/AN/AN/AN/AN/AN/AN/AN/AUPCUniverse PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACSTAcasti Pharma 3.00Buy$10.00221.54% UpsideETXEaton Vance Municipal Income 2028 Term Trust 0.00N/AN/AN/ANVHNovoheart 0.00N/AN/AN/ARENECartesian Growth Co. II 0.00N/AN/AN/AUPCUniverse Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACSTAcasti PharmaN/AN/AN/AN/A$6.57 per shareN/AETXEaton Vance Municipal Income 2028 Term Trust$6.94MN/AN/AN/AN/AN/ANVHNovoheartC$423.50K236.08C$0.07 per share7.46C$0.12 per share4.34RENECartesian Growth Co. IIN/AN/A$0.40 per share29.45($0.64) per shareN/AUPCUniverse Pharmaceuticals$23.02M0.01N/AN/A$163.50 per share0.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACSTAcasti Pharma-$12.85M-$1.44N/AN/AN/AN/A-13.61%-11.56%N/AETXEaton Vance Municipal Income 2028 Term TrustN/AN/A0.00∞N/AN/AN/AN/AN/ANVHNovoheartN/A-C$0.04N/A∞N/AN/AN/AN/AN/ARENECartesian Growth Co. II$11.44MN/A0.00∞N/AN/A-51.08%5.43%8/13/2025 (Estimated)UPCUniverse Pharmaceuticals-$6.16MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACSTAcasti PharmaN/AN/AN/AN/AN/AETXEaton Vance Municipal Income 2028 Term Trust$0.703.88%N/AN/AN/ANVHNovoheartN/AN/AN/AN/AN/ARENECartesian Growth Co. IIN/AN/AN/AN/AN/AUPCUniverse PharmaceuticalsN/AN/AN/AN/AN/ALatest UPC, ETX, ACST, NVH, and RENE DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/3/2025ETXEaton Vance Municipal Income 2028 Term Trustmonthly$0.07825.2%6/16/20256/16/20256/30/20255/2/2025ETXEaton Vance Municipal Income 2028 Term Trustmonthly$0.07825.2%5/15/20255/15/20255/30/20254/2/2025ETXEaton Vance Municipal Income 2028 Term Trustmonthly$0.07825.1%4/15/20254/15/20254/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACSTAcasti PharmaN/A7.867.86ETXEaton Vance Municipal Income 2028 Term TrustN/AN/AN/ANVHNovoheart27.626.136.05RENECartesian Growth Co. IIN/A0.090.09UPCUniverse PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACSTAcasti Pharma6.08%ETXEaton Vance Municipal Income 2028 Term TrustN/ANVHNovoheartN/ARENECartesian Growth Co. II58.96%UPCUniverse Pharmaceuticals0.18%Insider OwnershipCompanyInsider OwnershipACSTAcasti Pharma13.51%ETXEaton Vance Municipal Income 2028 Term TrustN/ANVHNovoheartN/ARENECartesian Growth Co. II26.60%UPCUniverse Pharmaceuticals57.38%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACSTAcasti Pharma329.40 million8.77 millionNot OptionableETXEaton Vance Municipal Income 2028 Term Trust35N/AN/ANot OptionableNVHNovoheartN/A188.64 millionN/ANot OptionableRENECartesian Growth Co. II221.62 million15.87 millionNot OptionableUPCUniverse Pharmaceuticals22043,000731,000Not OptionableUPC, ETX, ACST, NVH, and RENE HeadlinesRecent News About These CompaniesPharma Playbook: What Practitioners Can Learn from Early UPC LitigationMay 14, 2025 | ipwatchdog.comIUniverse Pharmaceuticals Reports Full Year 2024 EarningsMay 3, 2025 | finance.yahoo.comUniverse Pharmaceuticals INC Announces Share Consolidation Effective March 24, 2025March 20, 2025 | quiverquant.comQUniverse Pharmaceuticals INC Announces Share ConsolidationMarch 20, 2025 | gurufocus.comUniverse Pharmaceuticals INC Announces Share ConsolidationMarch 20, 2025 | investing.comUniverse Pharmaceuticals INC Announces Share ConsolidationMarch 20, 2025 | globenewswire.comUniverse Pharmaceuticals Approves Share Consolidation at Extraordinary MeetingMarch 11, 2025 | tipranks.comUniverse Pharmaceuticals INC Faces Potential Delisting from Nasdaq Due to Delinquent Annual Report FilingFebruary 25, 2025 | quiverquant.comQUniverse Pharmaceuticals INC Receives Staff Determination Notice from Nasdaq Related to Delayed Annual ReportFebruary 25, 2025 | globenewswire.comUniverse Pharmaceuticals proposes revised share consolidationFebruary 11, 2025 | msn.comUniverse Pharmaceuticals (NASDAQ:UPC) Stock, Short Interest ReportFebruary 10, 2025 | benzinga.comUniverse Pharmaceuticals INC.: Universe Pharmaceuticals INC Receives Nasdaq Delisting Notice Subject to Hearing RequestFebruary 6, 2025 | finanznachrichten.deUPC’s Unexpected Plunge: What’s Next?February 5, 2025 | bovnews.comBUniverse Pharmaceuticals gets Nasdaq delisting noticeFebruary 4, 2025 | markets.businessinsider.comUniverse Pharmaceuticals INC Faces Nasdaq Delisting Due to Low Share PriceFebruary 3, 2025 | quiverquant.comQUniverse Pharmaceuticals INC Receives Nasdaq Delisting Notice Subject to Hearing RequestFebruary 3, 2025 | globenewswire.comUniverse Pharmaceuticals announces shareholder meetingJanuary 30, 2025 | msn.comUniverse Pharmaceuticals stock hits 52-week low at $0.48 amid steep declineJanuary 29, 2025 | msn.comUniverse Pharmaceuticals Inc (UPC) Stock: A Deeper Look at Its True PotentialDecember 29, 2024 | bovnews.comBUniverse Pharmaceuticals Files Registration for 37.5 Million SharesDecember 14, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack Mode3 Biotech Stocks to Watch: Iovance, Neurocrine & VikingBy Chris Markoch | June 29, 2025View 3 Biotech Stocks to Watch: Iovance, Neurocrine & VikingUPC, ETX, ACST, NVH, and RENE Company DescriptionsAcasti Pharma NASDAQ:ACSTAcasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.Eaton Vance Municipal Income 2028 Term Trust NYSE:ETX$18.04 0.00 (0.00%) As of 06/30/2025 03:58 PM EasternEaton Vance Municipal Income 2028 Term Trust is a closed ended fixed income mutual fund launched and managed by Eaton Vance Management. It invests in the fixed income markets. The fund invest in stocks of companies operating across the diversified sectors. It was previously known as Eaton Vance Municipal Income Term Trust. Eaton Vance Municipal Income 2028 Term Trust was formed on March 28, 2013 and is domiciled in the United States.Novoheart CVE:NVHC$0.53 +0.01 (+1.92%) As of 11/20/2020Novoheart Holdings Inc. operates as a stem cell biotechnology company in the United States. The company offers an array of next-generation human heart tissue prototypes. It provides MyHeart platform products, including human pluripotent stem cell-derived cardiomyocytes, human ventricular cardiac anisotropic sheet assays, and human ventricular cardiac tissue strips assays. The company also offers screening and phenotyping services; and consultation services, including mapping and designing preclinical studies that involve human embryonic or induced pluripotent stem cell-derived cardiomyocytes, prototyping custom bioreactor designs, and developing custom software for streamlining of screening platforms and analysis of acquired data. Novoheart Holdings Inc. has a collaboration with AstraZeneca to develop human-specific in vitro functional model of heart failure with preserved ejection fraction. The company is based in Vancouver, Canada.Cartesian Growth Co. II NASDAQ:RENE$11.75 0.00 (0.00%) As of 05/13/2025Cartesian Growth Corp. II operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on October 13, 2021 and is headquartered in New York, NY.Universe Pharmaceuticals NYSE:UPC$3.75 +0.10 (+2.74%) As of 06/30/2025 04:00 PM EasternUniverse Pharmaceuticals INC, through its subsidiaries, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is based in Ji'An, China. Universe Pharmaceuticals INC operates as a subsidiary of Sununion Holding Group Limited. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
